Effect of pulse high-volume hemofiltration on Toll-like receptor in patients with severe sepsis

Zhang,Ning; Zhang,Jian; Cao,Zhuo; Deng,Liancheng; Wu,Yifen; Liu,Hong; Qiu,Zeliang

doi:10.3892/etm.2016.3473

Effect of pulse high-volume hemofiltration on Toll-like receptor in patients with severe sepsis

Authors:
- Ning Zhang
- Jian Zhang
- Zhuo Cao
- Liancheng Deng
- Yifen Wu
- Hong Liu
- Zeliang Qiu
View Affiliations

Affiliations: Department of Critical Care Medicine, Lishui People's Hospital, Lishui, Zhejiang 323000, P.R. China, Department of Respiratory Medicine, Lishui People's Hospital, Lishui, Zhejiang 323000, P.R. China, Department of Critical Care Medicine, The Affiliated Zhoupu Hospital of Shanghai University of Medicine & Health Sciences, Shanghai 201318, P.R. China
Published online on: June 23, 2016 https://doi.org/10.3892/etm.2016.3473
Pages: 1377-1382
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression level and prognosis of Toll-like receptor 2 (TLR2) mRNA in peripheral blood mononuclear cells of patients with severe sepsis after applying pulse high-volume hemofiltration (PHVHF) were investigated. Sustained PHVHF treatment was carried out on 40 patients on the basis of conventional treatment for up to 72 h. Acute physiology and chronic health evaluation (APACHE) Ⅱ scores of patients were compared before and after the treatment. CD4+, CD8+ lymphocyte counts and ratios in the peripheral blood were detected using FASort before and 24 and 48 h of PHVHF treatment. Enzyme‑linked immunosorbent assay was adopted to detect tumor necrosis factor‑α (TNF‑α) and interleukin‑10 (IL‑10) concentrations in plasma at different time points before and after 24, 48 and 72 h of treatment, while semi‑quantitative reverse transcription-polymerase chain reaction technology was used to test TLR2 mRNA expression. After PHVHF treatment, APACHE Ⅱ, Sequential Organ Failure Assessment scores were decreased (P<0.05). After 72 h of PHVHF treat-ment, TNF-α, IL-10, TLR2 mRNA expression levels in the plasma of patients were significantly decreased compared to before treatment (P<0.05), and the IL-10 / TNF-α ratio was much higher than before treatment (p<0.05). In conclusion, PHVHF can restore the pro‑inflammatory/anti‑inflammatory balance of the body, thereby improving the overall condition of the patients by removing inflammatory mediators and lowering TLR2 expression of mononuclear cell surface in peripheral blood.

View Figures

View References

1	Li C, Zhang P, Cheng X and Chen J: High-volume hemofiltration reduces the expression of myocardial tumor necrosis factor-alpha in septic shock pigs. Artif Organs. 37:196–202. 2013. View Article : Google Scholar : PubMed/NCBI
2	Boussekey N, Chiche A, Faure K, Devos P, Guery B, D'Escrivan T, Georges H and Leroy O: A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med. 34:1646–1653. 2008. View Article : Google Scholar : PubMed/NCBI
3	Cornejo R, Downey P, Castro R, Romero C, Regueira T, Vega J, Castillo L, Andresen M, Dougnac A, Bugedo G and Hernandez G: High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med. 32:713–722. 2006. View Article : Google Scholar : PubMed/NCBI
4	Cole L, Bellomo R, Journois D, Davenport P, Baldwin I and Tipping P: High-volume haemofiltration in human septic shock. Intensive Care Med. 27:978–986. 2001. View Article : Google Scholar : PubMed/NCBI
5	Oberholzer A, Oberholzer C and Moldawer LL: Sepsis syndromes: Understanding the role of innate and acquired immunity. Shock. 16:83–96. 2001. View Article : Google Scholar : PubMed/NCBI
6	Moss RB, Moll T, El-Kalay M, Kohne C, Soo HW, Encinas J and Carlo DJ: Th1/Th2 cells in inflammatory disease states: Therapeutic implications. Expert Opin Biol Ther. 4:1887–1896. 2004. View Article : Google Scholar : PubMed/NCBI
7	Abbas AK, Murphy KM and Sher A: Functional diversity of helper T lymphocytes. Nature. 383:787–793. 1996. View Article : Google Scholar : PubMed/NCBI
8	Harty JT, Tvinnereim AR and White DW: CD8+ T cell effector mechanisms in resistance to infection. Annu Rev Immunol. 18:275–308. 2000. View Article : Google Scholar : PubMed/NCBI
9	Walter U and Santamaria P: CD8⁺ T cells in autoimmunity. Curr Opin Immunol. 17:624–631. 2005. View Article : Google Scholar : PubMed/NCBI
10	Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell. 124:783–801. 2006. View Article : Google Scholar : PubMed/NCBI
11	Holmes JH IV, Connolly NC, Paull DL, Hill ME, Guyton SW, Ziegler SF and Hall RA: Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes. Infamm Res. 51:579–586. 2002. View Article : Google Scholar
12	Hotchkiss RS and Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003. 348:138–150. 2003.
13	Bone RC: Immunologic dissonance: a continuing evolution in our understanding of the systemic infammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med. 125:680–687. 1996. View Article : Google Scholar : PubMed/NCBI
14	Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL and Ramsay G: SCCM/ESICM/ACCP/ATS/SIS: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 31:1250–1256. 2003. View Article : Google Scholar : PubMed/NCBI
15	Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al: Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 41:580–637. 2013. View Article : Google Scholar : PubMed/NCBI
16	Martin GS, Mannino DM, Eaton S and Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 348:1546–1554. 2003. View Article : Google Scholar : PubMed/NCBI
17	Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P and La Greca G: Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial. Lancet. 356:26–30. 2000. View Article : Google Scholar : PubMed/NCBI
18	Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G and Matson JR: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 28:3581–3587. 2000. View Article : Google Scholar : PubMed/NCBI
19	Brendolan A, D'Intini V, Ricci Z, Bonello M, Ratanarat R, Salvatori G, Bordoni V, De Cal M, Andrikos E and Ronco C: Pulse high volume hemofiltration. Int J Artif Organs. 27:398–403. 2004.PubMed/NCBI
20	Chu LP, Zhou JJ, Yu YF, Huang Y and Dong WX: Clinical effects of pulse high-volume hemofiltration on severe acute pancreatitis complicated with multiple organ dysfunction syndrome. Ther Apher Dial. 17:78–83. 2013. View Article : Google Scholar : PubMed/NCBI
21	Peng Z, Pai P, Han-Min W, Jun Z, Hong-Bao L, Rong L and Chen H: Evaluation of the effects of pulse high-volume hemofiltration in patients with severe sepsis: A preliminary study. Int J Artif Organs. 33:505–511. 2010.PubMed/NCBI
22	Ratanarat R, Brendolan A, Ricci Z, Salvatori G, Nalesso F, de Cal M, Cazzavillan S, Petras D, Bonello M, Bordoni V, Cruz D, Techawathanawanna N and Ronco C: Pulse high-volume hemofiltration in critically ill patients: A new approach for patients with septic shock. Semin Dial. 19:69–74. 2006. View Article : Google Scholar : PubMed/NCBI
23	Ratanarat R, Brendolan A, Piccinni P, Dan M, Salvatori G, Ricci Z and Ronco C: Pulse high-volume haemofiltration for treatment of severe sepsis: Effects on hemodynamics and survival. Crit Care. 9:R294–R302. 2005. View Article : Google Scholar : PubMed/NCBI
24	Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM and Karl IE: Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol. 174:5110–5118. 2005. View Article : Google Scholar : PubMed/NCBI
25	Chen X and Ye J and Ye J: Analysis of peripheral blood lymphocyte subsets and prognosis in patients with septic shock. Microbiol Immunol. 55:736–742. 2011. View Article : Google Scholar : PubMed/NCBI
26	Walley KR, Lukacs NW, Standiford TJ, Strieter RM and Kunkel SL: Balance of inflammatory cytokines related to severity and mortality of murine sepsis. Infect Immun. 64:4733–4738. 1996.PubMed/NCBI
27	van der Poll T and Opal SM: Host-pathogen interactions in sepsis. Lancet Infect Dis. 8:32–43. 2008. View Article : Google Scholar : PubMed/NCBI
28	Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, Miller-Graziano C, Moldawer LL, Mindrinos MN, Davis RW, Tompkins RG and Lowry SF: A network-based analysis of systemic inflammation in humans. Nature. 437:1032–1037. 2005. View Article : Google Scholar : PubMed/NCBI
29	Yang RB, Mark MR, Gray A, Huang A, Xie MH, Zhang M, Goddard A, Wood WI, Gurney AL and Godowski PJ: Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature. 395:284–288. 1998. View Article : Google Scholar : PubMed/NCBI
30	Zeytun A, van Velkinburgh JC, Pardington PE, Cary RR and Gupta G: Pathogen-specific innate immune response. Adv Exp Med Biol. 598:342–357. 2007. View Article : Google Scholar : PubMed/NCBI
31	Zhang FX, Kirschning CJ, Mancinelli R, Xu XP, Jin Y, Faure E, Mantovani A, Rothe M, Muzio M and Arditi M: Bacterial lipopolysaccharide activates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem. 274:7611–7614. 1999. View Article : Google Scholar : PubMed/NCBI
32	Lorne E, Dupont H and Abraham E: Toll-like receptors 2 and 4: Initiators of non-septic inflammation in critical care medicine? Intensive Care Med. 36:1826–1835. 2010. View Article : Google Scholar : PubMed/NCBI
33	Kawai T and Akira S: The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat Immunol. 11:373–384. 2010. View Article : Google Scholar : PubMed/NCBI
34	Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, Rutschmann S, Du X and Hoebe K: Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol. 24:353–389. 2006. View Article : Google Scholar : PubMed/NCBI